Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) reports the U.S. District Court for the Southern District of New York has issued a favorable set of claim construction rulings in the Company s patent infringement lawsuit against Sandoz Inc./Momenta Pharmaceuticals, Inc. and Mylan/Natco regarding Teva s multiple sclerosis (MS) product, Copaxone.
The Court adopted all relevant Teva claim construction interpretations and rejected all of the claim construction interpretations put forth by Sandoz/Momenta and Mylan/Natco. In addition, the Court denied Mylan s motion for summary judgment that the patents at issue are invalid for indefiniteness.
Market Data 
Markets 
AI
